(Total Views: 478)
Posted On: 08/06/2019 5:03:43 PM
Post# of 148985
Thank you for the response. A couple of follow up thoughts, though you may not have this info:
- Was this patient selected solely because of type of her cancer profile, or in addition to type, she had a very limited life expectancy (hence FDA takes the risk into approval)? If so, any guess on the amount of time she might have, i.e. w/o the Leronlimab treatment?
- Do patients like her have other collateral damage that stopping the cancer spreading may still not be sufficient to extend her life? That is, if a patient is very late stage, can other causes overwhelm the clarity of the test results?
Sad questions but trying to determine the range of outcomes. Thanks!
- Was this patient selected solely because of type of her cancer profile, or in addition to type, she had a very limited life expectancy (hence FDA takes the risk into approval)? If so, any guess on the amount of time she might have, i.e. w/o the Leronlimab treatment?
- Do patients like her have other collateral damage that stopping the cancer spreading may still not be sufficient to extend her life? That is, if a patient is very late stage, can other causes overwhelm the clarity of the test results?
Sad questions but trying to determine the range of outcomes. Thanks!
(0)
(0)Scroll down for more posts ▼
